- Invitrogen Corp., which makes kits used by researchers for gene cloning, on Tuesday reported a loss for the fourth quarter on consolidation and acquisition charges.

The company lost $100.2 million, or $2.08 per share, compared with a profit of $45.5 million, or 87 cents per share, during the same period a year prior. Excluding charges, the company said it earned $1.01 per share.

Analysts polled by Thomson Financial expected profit of 73 cents per share, excluding charges.

Revenue rose to $329.8 million from $325.3 million. Analysts expected revenue of $314.7 million.

For the full year, the company lost $191 million, or $3.72 per share, compared with a profit of $132 million, or $2.33 per share. Revenue rose to $1.26 billion from $1.2 billion.

The company said it expects revenue from continuing operations to increase by the low-to-mid single digits in 2007. Profit, excluding charges, is expected to increase by two to three times the rate of revenue.

Shares of Invitrogen fell 53 cents to close at $60.36 on the Nasdaq. IN aftermarket electronic trading, shares gained $3.14, or 5.2 percent, to $63.50.